Industry Workshops
Sunday, September 11, 2011
IWSB100 Breakfast Workshop – Sixth Annual Business of Pathology Review
6:30–7:45 am
CME/CE Not Applicable
This session will focus on the factors that are changing revenue methodology in pathology today.
- Why the OIG thinks an audit is good for you
- Why you are not getting paid
- Who’s doing it right and why it works for them
Vachette Pathology will provide real-world examples from the auditing trenches and present concrete solutions to enhance the revenue of your practice.
Presented by 
IWSB110 Breakfast Workshop – Whole Slide Imaging: HER2 Scoring and Future Applications for Virtual Microscopy
6:30–7:45 am
CME/CE Not Applicable
This presentation will include a description of the findings of a study comparing quantitation of HER2 staining in breast cancer specimens using original glass slides and images acquired using a whole slide imaging system. In addition, the workshop will present examples of the use of whole slide imaging and image analysis of specimens from clinical and basic science studies of common diseases.
Presented by 
IWSB120 Breakfast Workshop – Regulatory Survival Kit: Coping With Unrelenting Government Scrutiny in Today’s Tough Compliance Environment
6:30–7:45 am
CME/CE Not Applicable
Pathology today faces a bewildering array of increasingly aggressive regulatory and CMS initiatives that have the potential to negatively impact pathology groups. For many groups, finding a path through this compliance minefield has become a major challenge. Rick Cooper, Esq., McDonald Hopkins, LLC, and Linda Liston, CPC, Director, Managed Care Services, McKesson Revenue Management Solutions will focus on current issues or initiatives such as RAC audits, ICD-10, IPERA, IPAB, PECOS and others. Identifying the issue, assessing the potential impact and developing a strategic plan are steps that will be discussed as well as ways to capitalize on opportunities in the current environment.
Presented by 
Monday, September 12, 2011
IWMB300 Breakfast Workshop – The Role of Biomarkers in the Management of Patients With CRC and AML
6:30–7:45 am
CME/CE Not Applicable
The management of several malignancies is becoming increasingly dependent on molecular and genetic classification of tumors. The complexity of these disease states raises many challenges in clinical practice today, particularly in the identification of therapeutic intervention as well as risk stratification. This workshop will focus on two diseases, colorectal cancer and acute myeloid leukemia, where the use of prognostic and predictive biomarkers has become an integral part of patient care.
Presented by Genzyme/US Labs
Genzyme Genetics and its logo are trademarks of Genzyme Corporation and used by Esoterix Genetic Laboratories, LLC, a wholly-owned subsidiary of LabCorp, under license. Esoterix Genetic Laboratories and LabCorp are operated independently from Genzyme Corporation.
IWMB310 Breakfast Workshop – Clinical Impact of Utilizing Multiplex IHC and Critical Antibodies in Diagnosis of Breast, Prostate, and Lung Cancers
6:30–7:45 am
CME/CE Not Applicable
Multiplex IHC technology was developed to simultaneously detect two or more antibodies in about the same time as it takes to do a single antibody IHC procedure. This has been a critical success in the clinical laboratory. A single Multiplex IHC can replace up to five single antibodies, reducing labor and reagent costs by > 50%. A key feature of this technology is that precious patient tissue is conserved while simultaneously testing for morphology distinct markers. This results in the generation of superior diagnostic data of increased predictive value as well as reducing time to result. The results are clear: Multiplex IHC is easy to interpret and gives additional information to pathologists while increasing their confidence in the results.
This workshop will feature three speakers who will review the use of this technology in the assessment and diagnosis of breast, prostate, and lung carcinomas:
- Breast Cancer Diagnosis: Assessing interobserver and intraobserver variability in the diagnosis of atypical ductal hyperplasia
- Prostate Cancer Diagnosis: The clinical utility of incorporating the chromosomal translocation specific ERG monoclonal antibody into every prostate panel
- PulmoPanel – A panel of six antibodies to differentiate between adenocarcinoma (LADC) and squamous cell carcinoma (SqCC) of the lung with 93% sensitivity and 100% specificity.
Presented by 
Monday, September 12, 2011
IWMD400 Dinner Workshop – Comprehensive Diagnostic Tools and Testing Services to Enhance Your Practice
6:15 pm
CME/CE Not Applicable
Speaker topics will include presentations on new novel markers and updates for the following:
- Lung cancer
- Breast cancer recurrence
- Hematologic malignancies
Moderator
Kenneth J. Bloom, MD, CMO, FCAP
Presented by 
IWMD410 Dinner Workshop – Effectively Competing as a Community-based Pathology Practice
6:15 pm
CME/CE Not Applicable
Centralized laboratories employ quality and service features, driving pathology from local markets into their laboratories. A lack of outreach resources and widening technology gap further weakens community pathologists’ hold on their market. During this workshop, learn strategies and tactics to compete against centralized labs, grow your practice, and remain independent‘keeping medicine local.
Presented by 